Umbilical cord blood transplantation without in vivo T-cell depletion for children with MHC class II deficiency - 06/06/18
The study was supported by the National Institute for Health Research and the GOSH Biomedical Research Centre. |
|
Disclosure of potential conflict of interest: R. Elfeky is employed by Bellicum Pharmaceutical. A. Worth has consultant arrangements with Biotest on cytomegalovirus-specific IgG. B. Gaspar has consultant arrangements and has stock/stock options with Orchard Therapeutics. W. Qasim has received grants from the National Institute for Health Research, Cellectis SA, Miltenyi Biotec, Cellmedica, Bellicum, and Autolus; has consultant arrangements with Autolus Ltd and Servier; has received royalties from Orchard; has stock/stock options from Autolus Ltd; and has received travel support from Miltenyi Biotec. P. Veys has received payment for lectures from EUSA, Health Hive, and Gilead. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 6
P. 2279 - juin 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?